Project Grant HT94252311050
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$911K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
The Department of Defense's Defense Health Agency awarded a $1,821,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Wistar Institute of Anatomy and Biology, an independent biomedical research institute in Philadelphia. The grant, awarded on May 15, 2024, supports research into the "Immunomodulatory Role of Acetate Metabolism in Breast Cancer" over a 3-year performance period ending on May 14, 2027. As a recognized leader in cancer,...
The U.S. Defense Health Agency awarded a $999,006 Project Grant to The Wistar Institute of Anatomy and Biology in Philadelphia, PA under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will fund research on Epstein-Barr virus-driven B-cell inflammation and central nervous system trafficking in multiple sclerosis. The Wistar Institute has previously served as a subcontractor on federal grants, providing...
The Department of Defense's Defense Health Agency awarded a $1,194,425 Project Grant to The Wistar Institute of Anatomy and Biology to support a 3-year research project titled "DEVELOPING RATIONAL APPROACHES FOR ACRAL MELANOMA" under the Military Medical Research and Development program (CFDA 12.420). The grant will fund basic, translational, and clinical research aimed at developing new treatments and advancing scientific understanding of acral melanoma, a rare form of skin cancer. As...
The Department of the Army Medical Command awarded New York University School of Medicine a $1,186,500 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through August 2024 to understand the transition from nevi to melanoma occurring within the skin epidermis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military...
The Trustees of the University of Pennsylvania received a $568,256 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2021 to July 31, 2024 to examine the role of microenvironment mechanics in sarcoma immune evasion. Through the support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims to transform...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The U.S. Defense Health Agency awarded a $234,000 Project Grant to the Medical College of Wisconsin, Inc. (MCW) under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "WHOLE-BRAIN RADIOPATHOMIC MAPPING OF GLIOBLASTOMA INFILTRATION", will fund advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The research, conducted from August 1, 2025 to July 31, 2027, aims to develop innovative...
The Department of Defense's Defense Health Agency awarded a $558,832 Project Grant to Tufts University School of Medicine under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2024. This grant will support research focused on "Targeting Differentiation Epitope in CD11b of Tumor-Associated Inflammatory Monocytes: A Novel Adjuvant Dendritic Cell Therapy Approach for Mucosal Melanoma." The research aims to develop an innovative dendritic cell-based...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...